<DOC>
	<DOCNO>NCT00972023</DOCNO>
	<brief_summary>RATIONALE : Dehydroepiandrosterone ( DHEA ) may slow growth tumor cell effective treatment woman breast cancer . PURPOSE : This phase I trial study well DHEA work treat woman undergo surgery stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>DHEA Treating Women Undergoing Surgery Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To identify effect adrenal steroid , dehydroepiandrosterone ( DHEA ) , tumor proliferation woman estrogen receptor-negative , progesterone receptor-negative , HER2/neu-negative , androgen receptor ( AR ) -positive stage I-III adenocarcinoma breast . Secondary - To study effect DHEA expression AR patient . - To assess effect DHEA change serum estrogen androgen hormone level ( e.g. , estrone , estradiol , testosterone , dihydrotestosterone , DHEA , DHEA-sulfate ) patient . - To assess toxicity DHEA patient . - To follow clinical course patient . OUTLINE : Patients receive oral dehydroepiandrosterone ( DHEA ) twice daily day -14 0 . Patients undergo surgery day 1 . Tissue sample collect baseline time surgery biomarker analysis ( androgen receptor , estrogen receptor , progesterone receptor , HER2/neu , Ki-67 , p53 ) IHC . Blood sample collect baseline completion treatment DHEA analysis serum hormone ( e.g. , estrone , estradiol , testosterone , dihydrotestosterone , DHEA , DHEA-sulfate ) cytokine level . After completion study therapy , patient follow 1 week every 6 month 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm invasive adenocarcinoma breast Stage I ( T1c ) , II , III disease ( AJCC stag system ) Lesion ≥ 1 cm breast image study ( mammogram , ultrasound , MRI ) HER2/neunegative tumor Planning receive dehydroepiandrosterone ( DHEA ) prior surgery Disease amenable surgery curative intent Scheduled undergo surgery immediately completion DHEA No locally advance metastatic disease amenable surgery Hormone receptor status : Estrogen receptor progesterone receptornegative tumor Androgen receptorpositive tumor PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % ANC ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 AST ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Bilirubin ≤ 2 time ULN Hemoglobin &gt; 9 g/dL Creatinine normal OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 1 week completion study therapy No history allergic reaction attribute compound similar chemical biological composition DHEA anastrozole No concurrent uncontrolled illness , include limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : See Disease Characteristics More 5 year since prior surgery , radiotherapy , biological therapy , hormone therapy , and/or chemotherapy invasive breast cancer No concurrent antineoplastic antitumor agents No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>triple-negative breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>